← Back to Search

UPLIFT-AD for Alzheimer's Disease (UPLIFT-AD Trial)

N/A
Recruiting
Led By Kathleen T Unroe, MD, MHA
Research Sponsored by Indiana University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Long-stay resident in an enrolled nursing home defined as not paying through Medicare Part A at the enrolled facility
Has a diagnosis of moderate to severe ADRD, as measured on the Minimum Data Set (MDS)
Must not have
Short-stay resident, defined as paying through Medicare Part A at the enrolled facility and/or receiving respite care
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1, 3, 6, 9, 12, 15, and 18 months
Awards & highlights

Summary

This trial will test whether the UPLIFT-AD model, which integrates primary and specialty palliative care, improves quality of life for nursing home residents with dementia and their caregivers, compared to usual care.

Who is the study for?
This trial is for long-stay residents in certain nursing homes who have moderate to severe Alzheimer's Disease, as confirmed by the Minimum Data Set (MDS), and have been there for over 30 days. Their family members or decision makers must speak English, as should the nursing facility staff involved.
What is being tested?
The study tests UPLIFT-AD, a model integrating primary and specialty Palliative Care into nursing facilities for older adults with dementia. It includes educating staff on Palliative Care, training them to provide it, and offering specialty care consultations.
What are the potential side effects?
Since this trial focuses on non-medical interventions like education and training in palliative care approaches rather than drugs or medical procedures, traditional side effects are not applicable. However, changes in resident health and quality of life will be monitored.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am a long-term resident not using Medicare Part A for payment.
Select...
I have been diagnosed with moderate to severe Alzheimer's or dementia.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am a short-stay resident covered by Medicare Part A or receiving respite care.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1, 3, 6, 9, 12, 15, and 18 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1, 3, 6, 9, 12, 15, and 18 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in End-of-Life Dementia - Comfort Assessment In Dying scale (EOLD-CAD)
Secondary study objectives
Change in End of Life Dementia - Satisfaction with Care (EOLD-SWC) scale
Change in End of Life Dementia - Symptom Management Scale.
Change in Family Distress in Advanced Dementia Scale.
+6 more

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Nursing Home-level UPLIFT-AD interventionExperimental Treatment1 Intervention
The UPLIFT-AD intervention consists of three major components delivered at the level of the nursing home: 1) in-house PC champions trained to a) facilitate advance care planning conversations with residents with Alzheimer's Disease and Related Dementias and their surrogate decision-makers, b) screen and follow up on residents' Palliative Care needs and c) serve as a liaison to Palliative Care consultants; 2) specialty Palliative Care consultant support providing individual consults for residents with complex Palliative Care needs; and 3) education on primary Palliative Care offered to all clinical NH staff.
Group II: Usual CareActive Control1 Intervention

Find a Location

Who is running the clinical trial?

Indiana UniversityLead Sponsor
1,019 Previous Clinical Trials
1,112,215 Total Patients Enrolled
University of Maryland, BaltimoreOTHER
705 Previous Clinical Trials
376,460 Total Patients Enrolled
National Institute on Aging (NIA)NIH
1,733 Previous Clinical Trials
28,053,003 Total Patients Enrolled

Media Library

Alzheimer's Disease Clinical Trial 2023: UPLIFT-AD Highlights & Side Effects. Trial Name: NCT04520698 — N/A
~468 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top